Department of Urology, University of Pisa, Pisa, Italy.
Eur Urol. 2010 May;57(5):780-90. doi: 10.1016/j.eururo.2010.01.014. Epub 2010 Jan 20.
According to current guidelines, radical orchidectomy is the standard treatment for testis tumours of malignant and unknown origin. Testis-sparing surgery (TSS) has recently been proposed as an alternative option in selected cases.
Our aim was to analyse the cumulative evidence for TSS in the treatment of adult malignant tumours of different histology, including notes on operative technique, indications, complications, and oncologic and functional outcome.
A systematic literature search of the Medline/PubMed database for full-length papers reporting on TSS for adult malignant tumours was performed up to September 2009. Bibliographies of retrieved articles and review articles were also examined. Only those articles with complete data on operative technique, complications, and oncologic or functional outcome were selected. Furthermore, published abstracts at major urologic meetings in the last decade (1999-2009) and guidelines on testis cancer from major oncologic and urologic medical associations were searched and evaluated.
No randomised controlled trials have compared TSS and radical orchidectomy; only retrospective outcome studies and case reports on TSS are available. In patients with small malignant germ cell tumours arising in both or in solitary testes, TSS coupled with local adjuvant radiotherapy ensures good oncologic control and is associated with a preserved endocrine function in most cases. In patients with small Leydig cell tumours, TSS can also be performed with elective indications (healthy contralateral testes), provided that pathology fails to reveal aggressive features. Finally, TSS is an option for patients with small ultrasound-detected, nonpalpable tumours even with elective indications because the incidence of benign definitive histology is high at approximately 80%. The overall complication rate is low (<6%). Data on exocrine and endocrine gonadal function, male body image, and health-related quality of life after TSS are still immature.
TSS can be safely adopted for the treatment of carefully selected cases of tumours of different histology. Prospective multicentre studies are warranted to further qualify TSS as a treatment option to be recommended as an alternative to radical orchidectomy and to explore the perceived functional advantages of testis preservation.
根据目前的指南,根治性睾丸切除术是治疗恶性和来源不明的睾丸肿瘤的标准治疗方法。最近,有人提议在某些选定的病例中采用保留睾丸手术(TSS)作为替代选择。
我们旨在分析 TSS 在治疗不同组织学成人恶性肿瘤中的累积证据,包括手术技术、适应证、并发症以及肿瘤学和功能结果方面的注意事项。
对截至 2009 年 9 月的 Medline/PubMed 数据库进行了系统的文献检索,以查找报告成人恶性肿瘤 TSS 的全文论文。还查阅了检索到的文章和综述文章的参考文献。只选择了那些提供完整手术技术、并发症和肿瘤学或功能结果数据的文章。此外,还搜索并评估了过去十年(1999-2009 年)在主要泌尿科会议上发表的已发表摘要以及主要肿瘤学和泌尿科医学协会的睾丸癌指南。
没有比较 TSS 和根治性睾丸切除术的随机对照试验;只有 TSS 的回顾性结果研究和病例报告可用。在双侧或单侧睾丸发生小的恶性生殖细胞瘤的患者中,TSS 联合局部辅助放疗可确保良好的肿瘤控制,并且在大多数情况下保留内分泌功能。在小的间质细胞瘤患者中,TSS 也可以在有选择性适应证(健康的对侧睾丸)的情况下进行,前提是病理检查未发现侵袭性特征。最后,对于即使有选择性适应证(因为大约 80%的病例最终组织学为良性)也可通过超声检测到的小的、不可触及的肿瘤患者,TSS 也是一种选择。总的并发症发生率较低(<6%)。关于 TSS 后外分泌和内分泌性腺功能、男性身体形象和健康相关生活质量的数据仍不成熟。
TSS 可以安全地用于治疗精心挑选的不同组织学肿瘤病例。需要进行前瞻性多中心研究,以进一步将 TSS 作为推荐替代根治性睾丸切除术的治疗选择进行限定,并探讨保留睾丸的功能优势。